Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 7/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409519 | 0.87 | TACR3 (0.45) | MGLLALDH1A1LMNATACR3 | |
| SCHEMBL25434178 | 0.86 | CCR5 (0.41) | ALDH1A1TACR3 | |
| SCHEMBL29497445 | 0.83 | GPR119 (0.45) | NAMPT | |
| SCHEMBL29426843 | 0.83 | MGLL (0.41) | NAMPTMGLLESR2 | |
| SCHEMBL26631403 | 0.83 | GPR119 (0.45) | NAMPT | |
| SCHEMBL26739045 | 0.83 | MGLL (0.41) | NAMPTMGLLESR2 | |
| SCHEMBL25435508 | 0.77 | FFAR4 (0.46) | MGLLLMNA | |
| SCHEMBL25262190 | 0.76 | MGLL (0.38) | NAMPTMGLL | |
| SCHEMBL30503564 | 0.75 | ESR2 (0.36) | NAMPTESR2ESR1 | |
| SCHEMBL25409715 | 0.75 | ESR2 (0.36) | NAMPTESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | NAMPT 3041/4885MGLL 1/4885ESR2 2213/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | NAMPT 3036/4885MGLL 1/4885ESR2 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.